

Prof. Iris Löw-Friedrich, M.D., Ph.D.
Member of the Supervisory Board

Year of birth	1960
Nationality	German
Place of residence	Ratingen, Germany
Main occupation	Member of several supervisory boards
Initial appointment	2026
End of current appointment	2029
Memberships in statutory Supervisory Boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises	
Evotec SE, Hamburg, Germany (publicly listed company)	Chairwoman of the Supervisory Board
Financière de Tubize S.A., Brussels, Belgium (publicly listed company)	Member of the Board
Fresenius SE & Co. KGaA, Bad Homburg, Germany (publicly listed company)	Member of the Supervisory Board
Satellos Bioscience Inc., Toronto, Canada (publicly listed company)	Member of the Board
Swedish Orphan Biovitrum AB (Sobi), Stockholm, Sweden (publicly listed company)	Member of the Board
Zealand Pharma A/S, Søborg, Denmark (publicly listed company)	Member of the Board

Prof. Iris Löw-Friedrich, M.D., Ph.D., has been a member of BioNTech's Supervisory Board since 2026. From 2008 to 2024 she was Chief Medical Officer, Global Head of Development and member of the Executive Committee at UCB S.A.. Between 1996 and 2008, she held various leadership roles at Schwarz Pharma AG/UCB S.A., BASF Pharma, and HMR/Aventis. She currently serves on several supervisory boards in the healthcare industry, including Fresenius SE & Co. KGaA.

Iris Löw-Friedrich studied medicine at the Goethe University in Frankfurt am Main and earned her doctorate in 1985 at the Max-Planck-Institute for Biophysics. Since 2000, she has been an adjunct professor of internal medicine.